Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation.
Publication
, Journal Article
Zhang, AD; Ross, JS
Published in: The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
September 2019
Surrogate endpoints are a common application of biomarkers to estimate clinical benefit in clinical trials, despite questions about reliability. This article discusses ongoing opportunities for their validation, in the context of a regulatory environment in which they are increasingly championed.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
DOI
EISSN
1748-720X
ISSN
1073-1105
Publication Date
September 2019
Volume
47
Issue
3
Start / End Page
393 / 395
Related Subject Headings
- United States Food and Drug Administration
- United States
- Reproducibility of Results
- Intersectoral Collaboration
- Humans
- Clinical Trials as Topic
- Biomarkers
- Applied Ethics
- 5001 Applied ethics
- 4804 Law in context
Citation
APA
Chicago
ICMJE
MLA
NLM
Zhang, A. D., & Ross, J. S. (2019). Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation. The Journal of Law, Medicine & Ethics : A Journal of the American Society of Law, Medicine & Ethics, 47(3), 393–395. https://doi.org/10.1177/1073110519876170
Zhang, Audrey D., and Joseph S. Ross. “Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation.” The Journal of Law, Medicine & Ethics : A Journal of the American Society of Law, Medicine & Ethics 47, no. 3 (September 2019): 393–95. https://doi.org/10.1177/1073110519876170.
Zhang AD, Ross JS. Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics. 2019 Sep;47(3):393–5.
Zhang, Audrey D., and Joseph S. Ross. “Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation.” The Journal of Law, Medicine & Ethics : A Journal of the American Society of Law, Medicine & Ethics, vol. 47, no. 3, Sept. 2019, pp. 393–95. Epmc, doi:10.1177/1073110519876170.
Zhang AD, Ross JS. Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics. 2019 Sep;47(3):393–395.
Published In
The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
DOI
EISSN
1748-720X
ISSN
1073-1105
Publication Date
September 2019
Volume
47
Issue
3
Start / End Page
393 / 395
Related Subject Headings
- United States Food and Drug Administration
- United States
- Reproducibility of Results
- Intersectoral Collaboration
- Humans
- Clinical Trials as Topic
- Biomarkers
- Applied Ethics
- 5001 Applied ethics
- 4804 Law in context